Integra LifeSciences reported Q3 2026 earnings of $0.59 per share, beating consensus estimates of $0.56, but revenues of $411.18 million missed expectations by 0.81%. The company received a Zacks Rank #3 (Hold) rating, suggesting market-in-line performance ahead. The Medical-Instruments industry ranks in the top 41% of Zacks industries.
STIM
Neuronetics, Inc. · NASDAQ
News
1 latestNo direct coverage yet · Showing articles that mention STIM
Headlines link to the publisher. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $STIM · 0 threads
Sign in to post on $STIM
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.